Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P10s-PADRE Vaccine with Chemotherapy in TNBC
NCT02938442Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Jan 2019
- Primary completion
- Jan 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of P10s-PADRE in triple-negative breast cancer (TNBC) (2 arms), sponsored by University of Arkansas. Primary endpoints: Safety and Tolerability Adverse Events, Pathologic Complete Response and 3 more. Started Jan 2019; status: completed.
02
Drugs
P10s-PADRE
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02938442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938442.